CYTO — Altamira Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.69m
- $2.16m
- CH₣0.16m
Annual cashflow statement for Altamira Therapeutics, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F/A |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.63 | -8.2 | -17.1 | -26.5 | -1.78 |
| Depreciation | |||||
| Non-Cash Items | -0.568 | 3.04 | 3.13 | 13.2 | -0.099 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.22 | 0.301 | 0.179 | 4.49 | 1.36 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -8.39 | -4.84 | -13.7 | -8.68 | -0.516 |
| Capital Expenditures | -3.02 | -2.32 | -3.33 | -2.14 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.018 | 0 | -0.179 | 0.001 | 0.002 |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3 | -2.31 | -3.51 | -2.14 | 0.002 |
| Financing Cash Flow Items | -0.952 | -0.637 | -0.161 | -0.055 | 1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 7.38 | 17 | 6.61 | 9.83 | 1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.01 | 9.87 | -10.3 | -0.969 | 0.485 |